NICE changes its mind on Janssen’s Erleada
Prostate cancer therapy now recommended for two indications within its marketing authorisation
Read More
Tag: Erleada
Janssen’s Erleada maintains quality of life for prostate cancer patients
New patient-reported outcomes data also shows Erleada did not worsen side effect burden
Read More
NICE turns down Janssen’s Erleada
Cost-effectiveness estimates have fallen above the threshold because of uncertain trial evidence
Read More
EU licence granted for Erleada in prostate cancer
Janssen’s new treatment for prostate cancer Erleada has been licensed by the European Commission.
Read More
CHMP backs four medicines for approval
Four medicines have taken a giant leap closer to approval having won the backing of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
